INS and cystic fibrosis-related diabetes: ETI therapy led to better glycemic control in insulin-dependent CFRD patients, shown by reduced HbA1c.Insulin requirements decreased in the first 6 months, but no further reduction was observed at 12 months.Significant improvements in pulmonary function, nutritional status, and quality of life were confirmed.More studies with longer follow-ups and larger samples are needed to fully understand ETI’s role il glucose regulation in CFRD patients.